Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma

A. Glasmacher*, T. Haferlach, M. Gorschluter, J. Mezger, C. Maintz, M. R. Clemens, Y. Ko, C. Hahn, R. Ubelacker, R. Kleinschmidt, F. Gieseler

*Corresponding author for this work
15 Citations (Scopus)


In order to replace the central venous line necessary for continuous infusion of vincristine and doxorubicin with high-dose dexamethasone (VAD) and to avoid hospitalization, we evaluated the efficacy and toxicity of oral idarubicin, vincristine and dexamethasone (VID) in patients with multiple myeloma. Vincristine (1.6 mg/m2, max 2 mg) was given as a bolus injection on day 1. Idarubicin was given in capsules 10 mg/m2/day for days 1-4 with an intraindividual dose escalation, 40 mg dexamethasone were given on days 1-4, 9-12, 17-20. Treatment cycles were repeated every 28 days. At this interim analysis, 53 patients have been entered into the ongoing trial; 46 patients are evaluable for toxicity. The median age was 60 years (interquartile range, 52-65). 46% were primary or secondary refractory, 20% had previously been treated with VAD and 30% had previously untreated disease, 4% had two or more relapses. Four patients died within 2 months from entry and were considered as early deaths (8.7%). 45% of the 42 patients evaluable for efficacy achieved a partial remission and 26% a minor remission. The median reduction of the M-component was 43% (interquartile range, 25-64%). VID is an effective and convenient alternative to VAD even in relapsed or refractory patients.

Original languageEnglish
Issue numberSUPPL. 5
Pages (from-to)S22-S26
Publication statusPublished - 1997


Dive into the research topics of 'Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this